Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock Holdings Lowered by Patten & Patten Inc. TN

Patten & Patten Inc. TN lowered its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 18.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 75,354 shares of the biotechnology company’s stock after selling 17,190 shares during the quarter. Patten & Patten Inc. TN owned 0.05% of Aurinia Pharmaceuticals worth $677,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in AUPH. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Aurinia Pharmaceuticals during the third quarter valued at approximately $3,330,000. Barclays PLC raised its holdings in shares of Aurinia Pharmaceuticals by 187.6% during the third quarter. Barclays PLC now owns 219,331 shares of the biotechnology company’s stock valued at $1,607,000 after acquiring an additional 143,072 shares during the period. PDT Partners LLC raised its holdings in shares of Aurinia Pharmaceuticals by 76.0% during the third quarter. PDT Partners LLC now owns 301,553 shares of the biotechnology company’s stock valued at $2,210,000 after acquiring an additional 130,204 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Aurinia Pharmaceuticals by 13.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company’s stock valued at $5,454,000 after acquiring an additional 89,940 shares during the period. Finally, State Street Corp raised its holdings in shares of Aurinia Pharmaceuticals by 2.3% during the third quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company’s stock valued at $21,587,000 after acquiring an additional 64,949 shares during the period. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH opened at $8.16 on Monday. The company’s 50 day moving average price is $8.01 and its 200 day moving average price is $7.94. Aurinia Pharmaceuticals Inc. has a 52 week low of $4.71 and a 52 week high of $10.67. The company has a market capitalization of $1.12 billion, a PE ratio of -54.40 and a beta of 1.26. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 19th.

Insider Activity at Aurinia Pharmaceuticals

In related news, CEO Peter Greenleaf sold 195,593 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the transaction, the chief executive officer now directly owns 1,953,892 shares of the company’s stock, valued at approximately $15,631,136. The trade was a 9.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Greg Keenan sold 8,305 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $8.23, for a total transaction of $68,350.15. Following the transaction, the insider now directly owns 153,484 shares in the company, valued at $1,263,173.32. The trade was a 5.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 343,898 shares of company stock valued at $2,753,094. Corporate insiders own 4.30% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.